Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Captures Overall Composite Edge (37.5 SELL vs 31.5 SELL), While PTN Leads 4–2 on Growth & Valuation Pillars

OBIO Overall Winner 6-Pillar Tally: PTN 4 – 2 OBIO Matrix Metrics: PTN 5 – 5 OBIO

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (37.5/100 SELL vs. 31.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. PTN trades at $6.12 (42.9x Forward P/E, -65.7% operating margin) versus OBIO at $7.12 (N/M Forward P/E, -195.4% operating margin).

  • Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.5/100 SELL vs. PTN 31.5/100 SELL) and 1.15β · 82% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both PTN (31.5/100 SELL) and OBIO (37.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs OBIO
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 82% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 69
RSI-14: 69.2 · SMA20: $5.93 · SMA50: $5.90

6-Pillar Scorecard Institutional Category Breakdown (PTN 4 – 2 OBIO)

Columns: Metric · PTN · OBIO
1. Valuation Multiples PTN
Forward P/E 42.9x N/M
Trailing P/E 42.9x N/M
PEG Ratio 1.62x N/M
EV / Revenue 0.1x 18.6x
2. Growth & Scale OBIO
Revenue Growth (YoY) -80.1% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M $31M
Market Cap $11.1M $570.6M
3. Profitability & Quality PTN
Gross Margin 6.2% 99.6%
Operating Margin -65.7% -195.4%
Net Profit Margin -63.5% -182.5%
Return on Equity (ROE) -877.5% -182.3%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$15M -$64M
Cash Flow Margin -113.6% N/A
Net Cash / Leverage $9.9M Net Cash $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 70.8% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (5) vs OBIO (5)
Institutional Metric PTN OBIO Criterion Row Edge
Market Capitalization
Scale
$11.1M $570.6M Larger Scale OBIO
Trailing P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Forward P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Revenue Growth (YoY)
Growth
-80.1% -89.4% Higher Growth PTN
Operating Margin (TTM)
Profitability
-65.7% -195.4% Higher Margin PTN
Net Profit Margin
Profitability
-63.5% -182.5% Higher Margin PTN
Return on Equity (ROE)
Capital Efficiency
-877.5% -182.3% Higher ROE OBIO
52-Week Range Position
Momentum
6% ($5–$31) 92% ($3–$7) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 1.15β · 82% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 37.5 / 100 (SELL) Higher Composite OBIO
Trailing 12M Revenue (USD)
Operating Scale
$13M $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · 18.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +28.9 pp
PTN: +1.74% · OBIO: +30.64%
3M Horizon OBIO +67.52 pp
PTN: -41.72% · OBIO: +25.8%
6M Horizon OBIO +138.7 pp
PTN: -59.81% · OBIO: +78.89%
1Y Horizon OBIO +113.62 pp
PTN: -43.29% · OBIO: +70.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PTN Revenue OBIO Revenue PTN Op. Margin OBIO Op. Margin Margin Leader
FY2018 $70M N/A 38.6% N/A PTN
FY2019 $60M N/A 59.3% N/A PTN
FY2020 $0M N/A -20007.6% N/A PTN
FY2022 $0M $0M -2491.6% -924.3% OBIO
FY2023 $0M $0M -668.7% -1866.2% PTN
FY2024 $0M $0M -501.0% -2437.5% PTN
FY2025 N/A $30M N/A -154.7% OBIO
FY2026 $10M N/A -65.7% N/A PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
32d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs OBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (37.5/100 SELL vs. 31.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. PTN trades at $6.12 (42.9x Forward P/E, -65.7% operating margin) versus OBIO at $7.12 (N/M Forward P/E, -195.4% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.5/100 SELL vs. PTN 31.5/100 SELL) and 1.15β · 82% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both PTN (31.5/100 SELL) and OBIO (37.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), PTN cumulative revenue shifted -85.7% while OBIO shifted N/A. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

PTN screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.